CiTSA, a comprehensive resource, which can provide a wealth of information about experimentally supported cancer immunotherapy signatures and also provide analysis tools based on single cell and bulk datasets. CiTSA stores 878 entries of experimentally supported associations between 412 signatures and 177 treatments of five mian immunotherapy categories across 30 cancer types.
    CiTSA also provides flexible online tools to identify and visualize molecular/cell feature and interaction, to perform function, correlation and survival analysis, and to execute cell clustering, cluster activity and cell-cell communication analysis based on single cell (307485 cells from 7 cancer types) and bulk (1045 samples from 16 cancer types) datasets. CiTSA provides a comprehensive and high-quality resource for studying biology molecules/cells act in tumor immunity and immunotherapy, and is helpful for understanding the molecular mechanism, discovering biomarkers, developing novel therapeutic targets and achieving the precision immunotherapy.

Immunotherapy types
     immune checkpoint therapy (12 treatments/drugs)
     adoptive cell therapy (36 treatments/drugs)
     cancer vaccine (30 treatments/drugs)
     oncolytic viruses (22 treatments/drugs)
     immunostimulant or targeting (63 treatments/drugs)
     combined immunotherapy (20 treatments/drugs)
Immunotherapy conditions
     response/non-response
     treatment/non-treatment

13 single cell datasets
     164 samples
     307485 cells
     7 cancer types
35 bulk datasets
     1045 samples
     16 cancer types